Advanced Brain Monitoring, Inc. announces the discovery of two novel sleep biomarkers linked to neurodegenerative disease at the annual meeting of the American Academy of Neurology (AAN).
“The biomarkers were discovered with the company’s Sleep Profiler™ while being used by National Institute of Health-funded research collaborators across seven U.S. institutions,” stated Daniel J. Levendowski, the studies’ lead author.
The first biomarker, called Non-REM Sleep with Hypertonia, was pronounced in patients with Parkinson’s disease, REM sleep behavior disorder and those with Dementia with Lewy Bodies or Parkinson’s Disease Dementia, but limited in those with mild cognitive impairment, Alzheimer’s Disease dementia or normal cognition. The second biomarker, Atypical Stage N3 Sleep, was found to be significantly greater in patients with synucleinopathies with dementia. Both biomarkers exhibited the characteristics one would expect for the prodromal assessment of synucleinopathies. The findings presented at AAN are summarized in this short video.
Source: Advanced Brain Monitoring
